ReviewInternational immunopharmacology2011
Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion.
Review in International immunopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization.Cell communication and signaling : CCS · 2025Review
- Late-onset neonatal sepsis: genetic differences by sex and involvement of the NOTCH pathway.Pediatric research · 2023Article
- Notch signaling pathway: architecture, disease, and therapeutics.Signal transduction and targeted therapy · 2022Review
- The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.Frontiers in immunology · 2022Review
- The paradoxical role of MDSCs in inflammatory bowel diseases: From bench to bedside.Frontiers in immunology · 2022Review
- Exploring the role of mast cells in the progression of liver disease.Frontiers in physiology · 2022Review
- TGF-β Enhances Immunosuppression of Myeloid-Derived Suppressor Cells to Induce Transplant Immune Tolerance Through Affecting Arg-1 Expression.Frontiers in immunology · 2022Article
- Notch signaling in female cancers: a multifaceted node to overcome drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata.Frontiers in immunology · 2018Article
- Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.Frontiers in immunology · 2018Review
- Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.Frontiers in immunology · 2018Review
- Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection.Immunology · 2017Article
- Stat3 and C/EBPβ synergize to induce miR-21 and miR-181b expression during sepsis.Immunology and cell biology · 2017Article
- Phenotype, development, and biological function of myeloid-derived suppressor cells.Oncoimmunology · 2016Review
- Myeloid-derived suppressor cells in B cell malignancies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells.Journal of leukocyte biology · 2014Article
- microRNAs as potential regulators of myeloid-derived suppressor cell expansion.Innate immunity · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic stem cells (HSCs) differentiate into mature lineage restricted blood cells under the influence of a complex network of hematopoietic cytokines, cytokine-mediated transcriptional regulators, and manifold intercellular signaling pathways. The classical model of hematopoiesis proposes that progenitor cells undergo a dichotomous branching into myelo-erythroid and lymphoid lineages. Nonetheless, erythroid and lymphoid restricted progenitors retain their myeloid potential, supporting the existence of an alternative 'myeloid-based' mechanism of hematopoiesis. In this case, abnormal pathology is capable of dysregulating hematopoiesis in favor of myelopoiesis. The accumulation of immature CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) has been shown to correlate with the presence of several hematopoietic cytokines, transcription factors and signaling pathways, lending support to this hypothesis. Although the negative role of MDSCs in cancer development is firmly established, it is now understood that MDSCs can exert a paradoxical, positive effect on transplantation, autoimmunity, and sepsis. Our conflicted understanding of MDSC function and the complexity of hematopoietic cytokine signaling underscores the need to elucidate molecular pathways of MDSC expansion for the development of novel MDSC-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.